PURPOSE: To investigate the feasibility, @entity137 and response rate, of concurrent chemoradiation therapy with @entity1311 / @entity900 in stage III locally advanced @entity1149 ( @entity1149 ). MATERIALS AND METHODS: Between May 1999 and December 2000, 80 @entity1 with @entity5 were enrolled in a prospective protocol. Radiotherapy was given to a total dose of 70.2 Gy (daily fraction of 1.8 Gy for 5 days), over an 8 week period, on the gross @entity5 volume, combined with chemotherapy. The concurrent chemotherapy consisted of @entity1311 (40 mg/m2) and 20 mg/m2 @entity900 per week for 8 consecutive weeks. All @entity1 received 3-D conformal radiotherapy using CT-simulated planning. Acute @entity137 were evaluated by the RTOG scale. The median follow-up period was 16 months, ranging from 3 to 29 months. RESULTS: Of the 80 @entity1 , 71 received treatment per protocol, with minor variation of protocol delivery. The median age of the @entity1 was 60 years. Karnofsky Performance status were 100 and 90 in 62 @entity1 , and 80 and 70 in 9, respectively. Weight loss of less than 5% for 6 months was observed in 22 @entity1 . The response to treatment was evaluated from the radiological findings. Complete and partial responses were observed in 8 and 51 @entity1 , respectively. Ultimately, 82% of @entity1 (included complete responses: 8 cases) obtained more than a partial response. Although, @entity1161 induced @entity2910 was the most common treatment related @entity137 , occurring in 44 @entity1 (69%), severe @entity1161 @entity2910 like, grade 3, was observed in only 3 @entity1 , and the most acute @entity137 had completely recovered 1 month following treatment. The overall 2-year actuarial and progression free survivals were 56 and 45%, respectively. CONCLUSION: This combined modality has activity with manageable @entity137 and 23 months in mean survival time in @entity1 with @entity5 . A longer follow up will be required to realise the expected higher survival of these results.

Preliminary Results of @entity1311 , XXXX and Concurrent High-Dose Radiation Therapy for Locally Advanced @entity1149 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'stage III NSCLC'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation'] @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']
@entity900 :: (MESH:D002945,Chemical) :: ['Cisplatin']
